Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $78
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and lowers the price target from $89 to $78.
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and lowers the price target from $89 to $78.